Alexion Pharmaceuticals, Inc. / Wilson Therapeutics AB
2018 · Acquisition/Merger · $855M · Complete
Announcement Sentiment
63
Positive
Alexion announced April 11, 2018 cash tender offer for Stockholm-based Wilson Therapeutics at SEK 232/share, total equity value ~$855M. Adds Phase 3 WTX101, a first-in-class copper-binding agent for Wilson disease, an inherited copper metabolism disorder. Strategic fit with Alexion's metabolic and neurologic rare disease focus to rebuild clinical pipeline post-Soliris dependence.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedApr 11, 2018
ClosedJun 25, 2018
Deal value$855M
Deal typeAcquisition/Merger
Therapeutic areaWilson disease
IndicationsWilson disease
Key assetsWTX101 (bis-choline tetrathiomolybdate)
MechanismFirst-in-class copper protein binding agent